Bacterial superglue enables easy development of efficient virus-like particle based vaccines

Journal of Nanobiotechnology

Volumn 14, Issue 1, 2016, Pages

  Thrane, Susan ^a,b   Janitzek, Christoph M ^a,b   Matondo, Sungwa ^c   Resende, Mafalda ^a,b   Gustavsson, Tobias ^a,b   Jongh, Willem Adriaan ^d   Clemmensen, Stine ^a,b,d   Roeffen, Will ^e   Vegte Bolmer, Marga ^e   Gemert, Geert Jan ^e   Sauerwein, Robert ^e   Schiller, John T ^f   Nielsen, Morten A ^a,b   Theander, Thor G ^a,b   Salanti, Ali ^a,b   Sander, Adam F ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Mental Health Center Glostrup   (Denmark)

^c KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^d TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; BINDING SITES; COST EFFECTIVENESS; DIAGNOSIS; MIXING; PROTEINS; VACCINES; VIRUSES;

ANTIBODY RESPONSE; CONJUGATION SYSTEM; COUPLING EFFICIENCY; MONOMERIC PROTEINS; NON-COMMUNICABLE DISEASE; PROOF OF CONCEPT; TRADITIONAL APPROACHES; VIRUS-LIKE PARTICLES;

DISEASES;

ANTIGEN; CAPSID PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTEIN; INTERLEUKIN 5; MEMBRANE PROTEIN; PFS25 PROTEIN; PROGRAMMED DEATH 1 LIGAND 1; SPYCATCHER; SPYTAG; UNCLASSIFIED DRUG; VAR2CSA PROTEIN; VIRUS LIKE PARTICLE VACCINE; BACTERIAL ANTIGEN;

ACINETOBACTER; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BACTERIOPHAGE; BINDING AFFINITY; BINDING SITE; CARBOXY TERMINAL SEQUENCE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CONJUGATION; GENE FUSION; IMMUNOGENICITY; LONGEVITY; MOUSE; NONHUMAN; VACCINE PRODUCTION; VIRUS LIKE AGENT; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; FEMALE; IMMUNOLOGY; PROCEDURES; VACCINATION;

ACINETOBACTER; ANIMALS; ANTIGENS, BACTERIAL; B-LYMPHOCYTES; BACTERIOPHAGES; CAPSID PROTEINS; FEMALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; VACCINATION; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84965002941     PISSN: None     EISSN: 14773155     Source Type: Journal    
DOI: 10.1186/s12951-016-0181-1     Document Type: Article

References (61)

1. Plotkin SA, Plotkin SL. The development of vaccines: how the past led to the future. Nat Rev Microbiol. 2011;9(12):889-93 (Nature Publishing Group).
2. Chackerian B. Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007;6(3):381-90.
3. Cubas R, Zhang S, Kwon SK, Sevick-Muraca EM, Li M, Chen CY, et al. Virus-like particle (VLP) lymphatic trafficking and immune response generation after immunization by different routes. J Immunother. 2009;32(2):118-28.
4. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787-96.
5. Bachmann MF, Rohrer UH, Kündig TM, Bürki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science. 1993;262:1448-51.
6. Hua Z, Hou B. TLR signaling in B cell development and activation. Cell Mol Immunol. 2013;10(2):103-6 (Nature Publishing Group).
7. Schödel F, Wirtz R, Peterson D, Hughes J, Warren R, Sadoff J, et al. Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med. 1994;180(3):1037-46.
8. Kratz PA, Böttcher B, Nassal M. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA. 1999;96(5):1915-20.
9. Pumpens P, Grens E. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology. 2001;44(2-3):98-114.
10. Smith MT, Hawes AK, Bundy BC. Reengineering viruses and virus-like particles through chemical functionalization strategies. Curr Opin Biotechnol. 2013;24(4):620-6 (Elsevier Ltd).
11. Sapsford KE, Algar WR, Berti L, Gemmill KB, Casey BJ, Oh E, et al. Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chem Rev. 2013;113(3):1904-2074.
12. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol. 2005;23:523-9.
13. Koho T, Ihalainen TO, Stark M, Uusi-Kerttula H, Wieneke R, Rahikainen R, et al. His-tagged norovirus-like particles: a versatile platform for cellular delivery and surface display. Eur J Pharm Biopharm. 2015;96:22-31.
14. Thrane S, Janitzek CM, Agerbæk MØ, Ditlev SB, Resende M, Nielsen MA, et al. A novel virus-like particle based vaccine platform displaying the placental malaria antigen VAR2CSA. PLoS One. 2015;10(11):e0143071.
15. Jegerlehner A, Tissot A, Lechner F, Sebbel P, Erdmann I, Kündig T, et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine. 2002;20(25-26):3104-12.
16. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, et al. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci USA. 2012;109(12):E690-7.
17. Tissot AC, Renhofa R, Schmitz N, Cielens I, Meijerink E, Ose V, et al. Versatile virus-like particle carrier for epitope based vaccines. PLoS ONE. 2010;5(3):3-10.
18. Wu Y, Narum DL, Fleury S, Jennings G, Yadava A. Particle-based platforms for malaria vaccines. Vaccine. 2015;33(52):7518-24.
19. Moreno A, Joyner C. ScienceDirect Malaria vaccine clinical trials: what' s on the horizon. Curr Opin Immunol. 2015;35:98-106 (Elsevier Ltd).
20. Wu Y, Ellis RD, Shaffer D, Fontes E, Malkin EM, Mahanty S, et al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs 25 formulated with montanide ISA 51. PLoS ONE. 2008;3(7):e2636.
21. Kaslow DC. Transmission-blocking vaccines. Chem Immunol. 2002;80(Malaria Immunology (2nd Edition)):287-307.
22. Coban C, Ishii KJ, Stowers AW, Keister DB, Klinman DM, Kumar N. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen. Infect Immun. 2004;72(1):584-8.
23. Stura EA, Kang AS, Stefanko RS, Calvo JC, Kaslow DC, Satterthwait AC. Crystallization, sequence and preliminary crystallographic data for transmission-blocking anti-malaria Fab 4B7 with cyclic peptides from the Pfs25 protein of P. falciparum. Acta Crystallogr D Biol Crystallogr. 1994;50(Pt 4):535-42 (International Union of Crystallography).
24. Salanti A, Staalsoe T, Lavstsen T, Jensen ATR, Sowa MPK, Arnot DE, et al. Selective upregulation of a single distinctly structured var gene in chondroitin sulphate A-adhering Plasmodium falciparum involved in pregnancy-associated malaria. Mol Microbiol. 2003;49(1):179-91.
25. Andersen P, Nielsen MA, Resende M, Rask TS, Dahlbäck M, Theander T, et al. Structural insight into epitopes in the pregnancy-associated malaria protein VAR2CSA. PLoS Pathog. 2008;4(2):e42.
26. Staalsoe T, Shulman CE, Bulmer JN, Kawuondo K, Marsh K, Hviid L. Variant surface antigen-specific IgG and protection against clinical consequences of pregnancy-associated Plasmodium falciparum malaria. Lancet. 2004;363(9405):283-9.
27. Nielsen MA, Resende M, de Jongh WA, Ditlev SB, Mordmüller B, Houard S, et al. The influence of sub-unit composition and expression system on the functional antibody response in the development of a VAR2CSA based Plasmodium falciparum placental malaria vaccine. PLoS ONE. 2015;10(9):e0135406.
28. Dahlbäck M, Jørgensen LM, Nielsen MA, Clausen TM, Ditlev SB, Resende M, et al. The chondroitin sulfate A-binding site of the VAR2CSA protein involves multiple N-terminal domains. J Biol Chem. 2011;286(18):15908-17.
29. Hedman K, Seppälä I. Recent rubella virus infection indicated by a low avidity of specific IgG. J Clin Immunol. 1988;8(3):214-21.
30. Lensen A, Van Druten J, Bolmer M, Van Gemert G, Eling W, Sauerwein R. Measurement by membrane feeding of reduction in Plasmodium falciparum transmission induced by endemic sera. Trans R Soc Trop Med Hyg. 1996;90(1):20-2.
31. Ott PA, Hodi FS, Robert C. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients. Clin Cancer Res. 2013;19(19):5300-9.
32. Garcia G, Taillé C, Laveneziana P, Bourdin A, Chanez P, Humbert M. Anti-interleukin-5 therapy in severe asthma. Eur Respir Rev. 2013;22(129):251-7.
33. Kingdom U, Business M, Corporation S, Sup EN, Cedex L, Kingdom U, et al. Programmable polyproteams built using twin peptide superglues. PNAS. 2016;113(5):1202-7.
34. Kumar R, Angov E, Kumar N. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding. Infect Immun. 2014;82(4):1453-9.
35. Jegerlehner A, Storni T, Lipowsky G, Schmid M, Pumpens P, Bachmann MF. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol. 2002;32:3305-14.
36. Barr BPJ, Green KM, Gibson HL, Bathurst IC, Quakyi IA, Kaslow DC. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med. 1991;174(November):1203-8.
37. Miura K, Keister DB, Muratova OV, Sattabongkot J, Long CA, Saul A. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer. Malar J. 2007;6(1):107.
38. Safaeian M, Porras C, Pan Y, Kreimer A, Schiller JT, Gonzalez P, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica vaccine trial. Cancer Prev Res. 2013;6(11):1242-50.
39. Tutterrow YL, Salanti A, Avril M, Smith JD, Pagano IS, Ako S, et al. High Avidity Antibodies to full-length VAR2CSA correlate with absence of Placental malaria. PLoS ONE. 2012;7(6):e40049.
40. Schiller J, Chackerian B. Why HIV virions have low numbers of envelope spikes: implications for vaccine development. PLoS Pathog. 2014;10(8):e1004254.
41. Chackerian B, Durfee MR, Schiller JT. Virus-like display of a neo-self antigen reverses B cell anergy in a B cell receptor transgenic mouse model. J Immunol. 2008;180(9):5816-25.
42. Übelhart R, Hug E, Bach MP, Wossning T, Dühren-von Minden M, Horn AHC, et al. Responsiveness of B cells is regulated by the hinge region of IgD. Nat Immunol. 2015;16(5):534-43.
43. Germann T, Bongartz M, Dlugonska H, Hess H, Schmitt E, Kolbe L, et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol. 1995;25(3):823-9.
44. Ravetch JV, Kinet JP. Fc receptors. Annu Rev Immunol. 1991;9:457-92.
45. Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol. 1981;11(12):1012-6.
46. Li Y, Leneghan DB, Miura K, Nikolaeva D, Brian IJ, Dicks MDJ, et al. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology. Nat Publ Gr. 2015;2016:1-13 (Nature Publishing Group).
47. Kubler-Kielb J, Majadly F, Wu Y, Narum DL, Guo C, Miller LH, et al. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25. Proc Natl Acad Sci USA. 2007;104(1):293-8.
48. Tissot AC, Maurer P, Nussberger J, Sabat R, Pfister T, Ignatenko S, et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet. 2008;371(9615):821-7.
49. Ambühl PM, Tissot AC, Fulurija A, Maurer P, Nussberger J, Sabat R, et al. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens. 2007;25(1):63-72.
50. Fettelschoss A, Zabel F, Bachmann MF. Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother. 2014;10(4):1-5.
51. Bachmann MF, Dyer MR. Therapeutic vaccination for chronic diseases: a new class of drugs in sight. Nat Rev Drug Discov. 2004;3(1):81-8.
52. Chackerian B, Briglio L, Albert PS, Lowy DR, Schiller JT. Induction of autoantibodies to CCR5 in macaques and subsequent effects upon challenge with an R5-tropic simian/human immunodeficiency virus. J Virol. 2004;78(8):4037-47.
53. Van Rompay KKA, Hunter Z, Jayashankar K, Peabody J, Montefiori D, LaBranche CC, et al. A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251. J Virol. 2014;88(4):2011-24.
54. Brune KD, Leneghan DB, Brian IJ, Ishizuka AS, Bachmann MF, Draper SJ, et al. Plug-and-Display: decoration of Virus-like particles via isopeptide bonds for modular immunization. Sci Rep. 2016;6:19234 (Nature Publishing Group).
55. Pashine A, Valiante NM, Ulmer JB. Targeting the innate immune response with improved vaccine adjuvants. Nat Med. 2005;11(4 Suppl):S63-8.
56. Buck CB, Pastrana DV, Lowy DR, Schiller JT. Efficient intracellular assembly of papillomaviral vectors. J Virol. 2004;78(2):751-7.
57. Wright KE, Hjerrild KA, Bartlett J, Douglas AD, Jin J, Brown RE, et al. Structure of malaria invasion protein RH5 with erythrocyte basigin and blocking antibodies. Nature. 2014;7(7527):427-30.
58. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology. 1989;98(Pt 2):165-73.
59. Miura K, Deng B, Tullo G, Diouf A, Moretz SE, Locke E, et al. Qualification of standard membrane-feeding assay with Plasmodium falciparum malaria and potential improvements for future assays. PLoS ONE. 2013;8(3):e57909.
60. Nielsen MA, Pinto VV, Resende M, Dahlbäck M, Ditlev SB, Theander TG, et al. Induction of adhesion-inhibitory antibodies against placental Plasmodium falciparum parasites by using single domains of VAR2CSA. Infect Immun. 2009;77(6):2482-7.
61. Haase RN, Megnekou R, Lundquist M, Ofori MF, Hviid L, Staalsoe T. Plasmodium falciparum parasites expressing pregnancy-specific variant surface antigens adhere strongly to the choriocarcinoma cell line BeWo. Infect Immun. 2006;74(5):3035-8.